Results 101 to 110 of about 7,772 (111)

Worldwide Use of RUCAM for Causality Assessment in 81,856 Idiosyncratic DILI and 14,029 HILI Cases Published 1993–Mid 2020: A Comprehensive Analysis

Medicines (Basel, Switzerland), 2020
Rolf Teschke, Gaby Danan
exaly  

Incidence and risk factors of anti‐tuberculosis drug induced liver injury (DILI): Large cohort study involving 4652 Chinese adult tuberculosis patients

Liver International, 2021
Huadong Yan, Ting Cai, Guruprasad P Aithal   +2 more
exaly  

Landscape of DILI-related adverse drug reaction in China Mainland

Acta Pharmaceutica Sinica B, 2022
exaly  

Prediction of human drug-induced liver injury (DILI) in relation to oral doses and blood concentrations

Archives of Toxicology, 2019
Franziska Kappenberg, Tim Brecklinghaus, Marcel Leist   +2 more
exaly  

Next‐Generation DILI Biomarkers: Prioritization of Biomarkers for Qualification and Best Practices for Biospecimen Collection in Drug Development

Clinical Pharmacology and Therapeutics, 2020
Rachel J Church, Paul B Watkins
exaly  

The Latin American DILI Registry Experience: A Successful Ongoing Collaborative Strategic Initiative

International Journal of Molecular Sciences, 2016
Fernando Bessone, María Isabel Lucena González, Raúl J Andrade   +2 more
exaly  

Current limitations and future opportunities for prediction of DILI from in vitro

Archives of Toxicology, 2016
Adrian B Roth
exaly  

The changing epidemiology of liver diseases in the Asia–Pacific region

Nature Reviews Gastroenterology and Hepatology, 2018
Jacob George, Junjie Huang, Colette Leung   +2 more
exaly  

Measures of BSEP Inhibition In Vitro Are Not Useful Predictors of DILI

Toxicological Sciences, 2018
Leslie Z Benet, Fcp
exaly  

Minimizing DILI risk in drug discovery — A screening tool for drug candidates

Toxicology in Vitro, 2015
Simone Schadt, Stefan Kustermann, Kuresh Youdim   +2 more
exaly